Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan
- PMID: 40603758
- DOI: 10.1007/s00535-025-02271-7
Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan
Abstract
Background: Inflammatory bowel disease (IBD) can occur at any age. In pediatric patients, the disease may present with a broader range of symptoms and more severe course than in adults, due to ongoing growth and development. Therefore, pediatric IBD often exhibits an atypical clinical course and laboratory findings. It is essential to recognize differences in disease presentation, differential diagnoses, and evaluation strategies specific to children. The revised Porto criteria, proposed by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) in 2014, are widely used globally, including in Japan, for the diagnosis of pediatric IBD.
Purpose: Despite the widespread use of these criteria, no formal diagnostic guidelines for pediatric IBD have been developed in Japan. We aimed to support future guideline development by summarizing important diagnostic considerations and clinical practices for pediatric IBD in Japan.
Methods: This review was developed based on relevant international diagnostic guidelines and the expert opinions of Japanese pediatric gastroenterologists. It outlines key clinical and laboratory evaluations, as well as current treatment and follow-up approaches.
Results: We summarized recommended diagnostic tests and clinical points that require special attention in children with suspected IBD. The article reflects both global standards and domestic clinical experience.
Conclusion: Although this article does not provide formal diagnostic criteria or assess evidence levels, it offers accurate and practical information to guide physicians and patients in the diagnosis and management of pediatric IBD in Japan.
Keywords: Children; Crohn’s disease; Inflammatory bowel disease; Pediatric; Ulcerative colitis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: Takashi Ishige received a consulting fee from AbbVie GK. Keisuke Jimbo received a grant Japan Society for the Promotion of Science KANENHI Grant-in-Aid for Scientific Research (c) [grant number 23K07361]. Fumihito Hirai received a consulting fee from AbbVie GK, EA pharma Co. Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD Co. Ltd., and a grant support from AbbVie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd.. Kenji Watanabe received a lecture fee from Takeda Pharmaceutical Co. Ltd., AbbVie GK, EA pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co. Ltd., JIMRO Co. Ltd.. Toshiaki Shimizu received a research grant from The Food Science Institute Foundation (Ryoshoku-kenkyukai). Tadakazu Hisamatsu received a grant support from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co. Ltd., Boston Scientific Corporation, Kissei Pharmaceutical Co. Ltd., a consulting fee from Mitsubishi Tanabe Pharma Corporation, EA pharma Co. Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb, Abivax, and a lecture fee from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Kissei Pharmaceutical Co. Ltd. All other authors declare no conflict of interest.
Similar articles
-
Vitamin D for the treatment of inflammatory bowel disease.Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD011806. doi: 10.1002/14651858.CD011806.pub2. Cochrane Database Syst Rev. 2023. PMID: 37781953 Free PMC article.
-
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article.
-
Patient education interventions for the management of inflammatory bowel disease.Cochrane Database Syst Rev. 2023 May 4;5(5):CD013854. doi: 10.1002/14651858.CD013854.pub2. Cochrane Database Syst Rev. 2023. PMID: 37172140 Free PMC article.
-
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6. Lancet Gastroenterol Hepatol. 2025. PMID: 39788134
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
LinkOut - more resources
Full Text Sources